---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-037053"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:16:53.988610+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aquestive reiterates Q1 2025 NDA filing for Anaphylm; notes FDA approval of non-injection epinephrine

## Summary
- CEO Daniel Barber applauds FDA approval of first non-injection-based epinephrine device for anaphylaxis.
- Reiterates NDA submission for Anaphylm (epinephrine) Sublingual Film in Q1 2025.
- Oral allergy syndrome (OAS) challenge study completion expected late Q3 or early Q4 2024.
- Full product launch of Anaphylm, if approved, targeted for end of 2025 or Q1 2026.

## SEC filing metadata
- accession: 0001628280-24-037053
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000162828024037053/0001628280-24-037053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000162828024037053/aqst-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-037053
- JSON: https://secwatch.observer/filing/0001628280-24-037053.json
- Plain text: https://secwatch.observer/filing/0001628280-24-037053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.